Recent News

• 12.04.2025 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 11.20.2025 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 11.17.2025 - Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
• 11.10.2025 - Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
• 11.06.2025 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 11.04.2025 - Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Recent Filings

• 12.04.2025 - 144 Report of proposed sale of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.02.2025 - 144 Report of proposed sale of securities
• 11.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 144 Report of proposed sale of securities
• 11.07.2025 - 4 Statement of changes in beneficial ownership of securities